Verity Pharmaceuticals acquires Pendopharm’s rights to commercialize ZEULIDE DEPOT™ for the Canadian oncology community – June 27, 2019

IVOZFO™ (fosfomycin for injection), a novel ‘first in class’ iv antibiotic approved for use in Canada. IVOZFO provides a new option for hard-to-treat infections, including multi-drug resistant superbugs – May 1, 2019

Verity Pharmaceuticals completes new drug submission to Health Canada for BCG bladder cancer treatment – November 1, 2018

Verity announces a licensing agreement for mitomycin with Vygoris, UK – November 1, 2018

Health Canada grants intravenous fosfomycin priority review status – July 16, 2018

Recent publication: intravenous fosfomycin potential in Canada and it’s role with MDR pathogens – July 11, 2018

Verity announces licensing agreement with Infectopharm to bring novel anti-infective to Canada – March 21, 2018

Verity Pharmaceuticals announces the appointment of Allan Silber to the board of directors – December 18, 2017

Verity Pharmaceuticals appoints scientific advisory board – September 4, 2016

Appointment of Mr. R. Rieder as chairman – July 5, 2016